The shareholdings of A.J. Aamund in NeuroSearch is diluted to less than 5% in connection with the company's issue of 300,000 new shares

Not for release, publication or distribution in Australia, Canada, Japan or the
United States. 



Announcement                                                                    



The shareholdings of A.J. Aamund in NeuroSearch is diluted to less than 5% in   
connection with the company's issue of 300,000 new shares                       

A.J. Aamund A/S (including President and CEO A. Aamund) today notified          
NeuroSearch that following the completion of the directed share offering today, 
A.J. Aamund will no longer hold more than 5% of the shares and voting rights in 
NeuroSearch.                                                                    

The shareholdings of A.J. Aamund (including President and CEO A. Aamund) in     
NeuroSearch will thus be diluted to 4.96% following the issue of the 300,000 new
shares.                                                                         


Thomas Hofman-Bang                                                              
Chairman                                                                        


Contact persons:                                                                
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118               
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate  
Communications, telephone: +45 4460 8212 or +45 4017 5103                       


This announcement contains certain statements that are forward-looking,         
including statements with respect to the development of the company's drug      
pipeline, its planned use of proceeds and its forecast for 2008. Such           
forward-looking statements are not guarantees of future performance and involve 
risks and uncertainties, and actual results may differ materially from those in 
the forward-looking statements as a result of various factors. Readers are      
cautioned not to place undue reliance on those forward-looking statements, which
speak only as of the date hereof.                                               


NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase
II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia      
(Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's  
disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS  
diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o.    
(Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I).  
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates   
and holds equity interests in several biotech companies.                        


This document does not constitute an offer to sell or the solicitation of an    
offer to buy the securities of NeuroSearch A/S (the “Securities”) in Australia, 
Canada, Japan or the United States, or in any other jurisdiction. The Securities
may not be offered or sold in the United States absent registration or an       
exemption from registration under the U.S. Securities Act of 1933, as amended.  
The issuer of the Securities has not registered, and does not intend to         
register, any portion of the offer in the United States, and does not intend to 
conduct a public offering of Securities in the United States.                   

This document is directed at and for distribution only to persons who (i) are   
outside of the United Kingdom, (ii)  have professional experience in matters    
relating to investments and fall within Article 19(5) ("investment              
professionals") of the Financial Services and Markets Act 2000 (Financial       
Promotion) Order 2005 (as amended, the “Financial Promotion Order”), or (iii)   
are persons falling within Article 49(2)(a) to (d) (“high net worth companies,  
unincorporated associations etc”) of the Financial Promotion Order,  (all such  
persons mentioned in (i), (ii), and (iii) together being referred to as         
“Relevant Persons”). The Securities are directed only at Relevant Persons and   
any investment or investment activity to which this webpage or other pages      
relate is available only to Relevant Persons and will be engaged in only with   
Relevant Persons.